Yap, Taz and Areg Expression in Eighth Cranial Nerve Schwannoma

Background Although the diagnosis and treatment of eighth cranial nerve (VIII CN) schwannoma (acoustic neuroma) has improved over the years, no factors capable of predicting tumor growth have been identified as yet. This study is a preliminary investigation of the expression in sporadic VIII CN schwannomas of Yes-associated protein (YAP), transcriptional coactivator with PDZ-binding motif (TAZ), and amphiregulin (AREG), a direct target gene of YAP and TAZ. The expression of YAP, TAZ and AREG was correlated with the volumetric dimensions of tumors on contrast-enhanced magnetic resonance imaging (ceMRI). Methods YAP, TAZ and AREG expression was assessed immunohistochemically in surgical specimens of 36 consecutive sporadic VIII CN schwannomas. 3D reconstructions of the tumors and their corresponding volumes in cm3 were obtained from measurements on ceMRI images using the OsiriX® software. Results We found a significant direct correlation between TAZ expression and VIII CN schwannoma volumes on latest preoperative ceMRI (p<0.0003). Mean TAZ expression was also significantly higher in VIII CN schwannomas with a volume ≥2.1 cm3 than in those with a volume <2.1 cm3 (p<0.0018). No significant correlations emerged for YAP or AREG expression and VIII CN schwannoma volume. Conclusions The immunohistochemical expression of TAZ (but not YAP or AREG) correlated significantly with schwannoma volume measured on ceMRI. Further investigations are needed to identify the biological factors influencing tumor proliferation (ideally secreted proteins like AREG) that might be detected using non-invasive approaches (i.e., blood samples).

[1]  A. Rutjes,et al.  Circulating Tumor Markers: A Guide to Their Appropriate Clinical Use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 2) , 2017, The International journal of biological markers.

[2]  A. Rutjes,et al.  Circulating Tumor Markers: A Guide to their Appropriate Clinical use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 1) , 2016, The International journal of biological markers.

[3]  L. Giacomelli,et al.  The prognostic role of the epithelial–mesenchymal transition markers E‐cadherin and Slug in laryngeal squamous cell carcinoma , 2015, Histopathology.

[4]  H. Ohgaki,et al.  Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas , 2015, Journal of neuropathology and experimental neurology.

[5]  P. Hogendoorn,et al.  Tumor Biology of Vestibular Schwannoma: A Review of Experimental Data on the Determinants of Tumor Genesis and Growth Characteristics , 2015, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[6]  A. Fassina,et al.  YAP immunoreactivity is directly related to pilomatrixoma size and proliferation rate , 2015, Archives of Dermatological Research.

[7]  M. Fassan,et al.  Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas. , 2014, The American journal of pathology.

[8]  Q. Wang,et al.  TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells , 2014, Molecular medicine reports.

[9]  P. Hupé,et al.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. , 2014, Neuro-oncology.

[10]  Li-juan Wang,et al.  Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma , 2014, Journal of immunology research.

[11]  Xaralabos Varelas,et al.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease , 2014, Development.

[12]  Daniel T. Montoro,et al.  Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis , 2014, The EMBO journal.

[13]  S. Dupont,et al.  Molecular Pathways Molecular Pathways : YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis , 2013 .

[14]  K. Guan,et al.  The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.

[15]  N. Yang,et al.  TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin , 2012, Cell cycle.

[16]  A. Mazzoni,et al.  Hearing preservation surgery in acoustic neuroma: long-term results , 2012, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[17]  P. Cayé-Thomasen,et al.  Epidemiology and natural history of vestibular schwannomas. , 2012, Otolaryngologic clinics of North America.

[18]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[19]  A. Mazzoni,et al.  Hearing preservation surgery in acoustic neuroma. Slow progress and new strategies , 2011, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[20]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[21]  J. Kissil,et al.  Merlin in organ size control and tumorigenesis: Hippo versus EGFR? , 2010, Genes & development.

[22]  Li Li,et al.  The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.

[23]  Jianmin Zhang,et al.  YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway , 2009, Nature Cell Biology.

[24]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[25]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[26]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[27]  Jianmin Zhang,et al.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.

[28]  P. Cayé-Thomasen,et al.  The Natural History of Vestibular Schwannoma , 2006, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[29]  M. Yaffe,et al.  The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. , 2005, The Biochemical journal.

[30]  J. Kanzaki,et al.  New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. , 2003, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[31]  M. Yaffe,et al.  TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins , 2000, The EMBO journal.